Test detail

This is an extremely important question. I will systematically explain it by breaking it down into three layers: facts, legal structures, and philosophical issues.

Pharmaceutical Company Liability Exemption, Contract Non-Disclosure Clauses, and the Problem of "Trust"

── Dissecting the Paradox Between Immunity and Trust

I. What Happened ── The Reality of Immunity

1. Legal Basis for Immunity

Regarding COVID-19 vaccine administration, governments decided to exempt pharmaceutical companies from compensation liability in cases where health damage occurs. The government implements necessary relief measures. This exemption is a special measure to promptly secure vaccines, and the government proposed related legislation.

Overseas pharmaceutical companies requested "government should cover compensation," and the new law adopted a policy where the government compensates for health damage caused by vaccines instead of pharmaceutical companies. The United States already conditionally granted immunity to pharmaceutical companies.

Specifically in America:

• The Public Readiness and Emergency Preparedness Act (PREP Act) exempts manufacturers from lawsuits related to vaccine injuries, with exceptions extremely limited.
• Persons injured by COVID vaccines must file claims with a fund managed by the Department of Health and Human Services.

2. Immunity Was Demanded by Pharmaceutical Companies as a "Contract Condition"

Manufacturers refused to agree to procurement contracts or ship vaccines without protection from compensation liability. According to AstraZeneca executives, the company was granted protection from legal claims arising from product use in bilateral contracts, which they stated was because they "cannot take risks." Going further back, in 2006, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) formally demanded that manufacturers participating in pandemic response must be protected from vaccine-related adverse event lawsuits.

In the Philippines case, immunity clauses were requirements set by vaccine manufacturers and the COVAX vaccine pool, stated as mandatory conditions for signing new coronavirus vaccine supply contracts.

II. The Reality of Non-Disclosure Clauses ── Secret Contracts

3. Contract Contents Are "Redacted" or "Secret"

Immunity clauses in agreements between the European Commission and Pfizer/BioNTech, and Moderna were substantively redacted (non-disclosure). While the conditions to which immunity does not apply are described, the sections describing those conditions are also redacted.

The public version of contracts concluded by the UK government also contains heavy redactions regarding liability clauses. A UK National Audit Office report noted that the government agreed to provide guarantees for risks that suppliers would normally bear under certain (non-disclosed) circumstances.

"By keeping contracts non-public or releasing heavily redacted documents, nobody knows when vaccines arrive, what happens if problems occur, or how much financial risk purchasers bear," transparency researchers point out.

4. Leaked Contracts Revealed Shocking Clauses

The citizens' organization Public Citizen obtained non-redacted versions or drafts of contracts between Pfizer and Albania, Brazil, Colombia, Dominican Republic, the European Commission, and Peru.

They revealed the following content:

①Government Non-Disclosure Clauses:

The Brazil contract contained clauses recognizing that long-term vaccine effects were unclear and unexpected adverse reactions were possible; clauses stating Pfizer bears no responsibility even if supply fails; clauses making the Brazilian government compensate when Pfizer faces liability; and various clauses allowing Pfizer to evade responsibility. Additionally, clauses prevented the Brazilian government from freely discussing the contract.

②Sovereign Asset Collateral Demands:

Pfizer demanded that multiple countries pledge sovereign assets—bank reserves, military bases, embassy buildings—as collateral guaranteeing compensation for damages arising from COVID vaccine administration.

In February 2021, Brazil rejected Pfizer's demands as "abusive." The demands included "abandoning foreign asset sovereignty for Pfizer," exemption from domestic law, and not penalizing Pfizer for vaccine delivery delays.

③Waiver of Sovereign Immunity and Secret Arbitration:

The UK contract required disputes be resolved by a three-person private arbitration panel of the International Chamber of Commerce (ICC); Albania draft and Brazil, Chile, Colombia, Dominican Republic, and Peru agreements required contract disputes be submitted to ICC arbitration under New York law. Pfizer demanded these countries waive sovereign immunity.

A government official stated: "In five years, when confidentiality agreements expire, we'll understand what actually happened in these negotiations." These contracts glimpsed how a single pharmaceutical enterprise gained power to silence governments, restrict supply, shift risks, and maximize profits during the worst public health crisis.

III. Philosophical and Structural Contradictions Between Immunity and Trust

Here lies the question's core: Why do people trust that products made by companies "they cannot sue" are safe?

5. Normal Conditions for "Trust" and the Collapsed Structure

Normally, product trust is supported by three pillars:

The distinctiveness of the COVID vaccine crisis is that all three pillars simultaneously collapsed.

6. "Urgency" Functioned as a Substitute for Trust

Many governments acknowledged that pharmaceutical companies undertook significant financial risks by developing and manufacturing vaccines at unprecedented speed (normally 10-15 years for vaccine implementation), and immunity was justified as compensation for this risk.

In each country, clinical trials and approval procedures were partially simplified, enabling implementation in shorter-than-usual timeframes. Many vaccines used new approaches like viral genetic information, creating potential for unexpected health damage after implementation.

In other words, governments forced citizens into the choice of "accept immunity and get vaccinated" through framing of "death from infection risk > side-effect risk."

7. The "Substitution of Responsibility" Trick

The immunity system's logic performs a substitution of trust from corporations to the nation-state.

• Corporations "cannot be sued," but victims "can receive government compensation"
• Thus citizens were required not to "trust pharmaceutical enterprises" but to "trust the state's compensation system"

But here lies a problem. Given that most research development and manufacturing costs (100% for AstraZeneca and Moderna) were covered by public funds, citizens have the right to clearly know these costs' breakdown and data.

That is:

• Development costs are public funds (taxes)
• Risks are borne by the nation-state (= citizens)
• Profits are acquired by enterprises
• Information is non-disclosed

This structure was established.

8. Non-Disclosure Clauses Create "Unverifiable Trust"

As long as transaction contents remain unexplained, who can use vaccines, when, and at what price—these decision rights remain with pharmaceutical enterprises. Critics argued there is no room for secrecy in this crisis-level pandemic.

"Verifiability" is a philosophical condition for trust. In a state of non-disclosed information, "trust" is not trust based on verification but rather submission to authority or consent through elimination of alternatives (= not true consent).

IV. Conclusion ── What This Structure Means

【Power Structure Diagram Under Pandemic】

  Pharmaceutical Company
  ├── Immunity: Cannot be sued even if harm occurs
  ├── Non-disclosure: Right not to disclose contract content
  ├── Sovereign asset collateral demands: Make nation-states guarantee with national assets
  └── Prohibition on disclosure: Governments cannot even make critical statements
       ↓
  Each National Government
  ├── "Takes on" compensation liability
  ├── Handles disputes through secret arbitration (away from public eye)
  └── Tells citizens "it's safe, get vaccinated"
       ↓
  Citizens
  ├── No information (non-disclosure)
  ├── No litigation rights (immunity)
  └── No alternatives (effectively mandatory)

Where Does "Trust" Reside?

Liability immunity destroys the fundamental contract relationship between enterprises and consumers that "trust is warranted because risks are borne." Non-disclosure clauses further make "trust through verification" impossible.

What remains is "trust as fiction" maintained by emotional pressure from urgency and dependence on state authority.

This is not so much a trust problem as an issue of information power asymmetry, and must be reconsidered as the fundamental hollowing-out of "informed consent" in democratic societies.

The pandemic led to pharmaceutical company liability exemptions because of the need for rapid vaccine development and supply. This exemption was implemented as part of emergency measures to accelerate vaccine development and save lives. The following explains the relationship between immunity and trust.

1. Reasons for Manufacturing Liability Exemption

• Rapid Development and Supply: During pandemics, vaccines must be widely distributed as quickly as possible. Exemption was applied to prevent companies from hesitating in development from fear of litigation.
• Government Compensation Systems: Most countries established systems where governments compensate for vaccine-caused damage. This ensures individuals receive appropriate compensation.

2. Trust in Safety

• Regulatory Authority Approval: Vaccines undergo strict regulatory scrutiny before public release, confirming safety and efficacy.
• Public Clinical Trial Data: Usually, clinical trial data are published and evaluated by scientists and medical professionals.

3. Contract Non-Disclosure Clauses

• Trade Secret Protection: Non-disclosure clauses in contracts protect commercial confidential information. However, product safety information is usually public, allowing third-party evaluation.
• Transparency Assurance: Even with non-disclosure clauses, systems typically enable regulatory authorities to appropriately evaluate safety and efficacy.

4. Foundation of Trust

• Scientific Communication: Scientists and medical professionals continuously communicate vaccine safety and efficacy information, helping general public maintain confidence.

These elements work together to establish trust in products manufactured by pharmaceutical companies.

I will explain how pharmaceutical companies were exempted from product liability during the pandemic, how this affects public trust in product safety, and the role of non-disclosure clauses in contracts.

Background of Manufacturing Liability Exemption During Pandemic

During the unprecedented crisis of the COVID-19 pandemic, many countries exempted pharmaceutical companies from limited or complete manufacturing liability for vaccines and therapeutics, known as "countermeasures." The main reasons are:

1. Incentive for Rapid Development and Supply: Given pandemic urgency, governments demanded pharmaceutical companies develop, manufacture, and supply vaccines and therapeutics at unprecedented speed. Development in shorter timeframes than usual carries risks of unexpected side effects and manufacturing problems. Companies feared assuming enormous compensation liability, so manufacturing liability exemption became a powerful incentive reducing risk and encouraging corporate investment in R&D and rapid market entry. In the 1980s, litigation threats caused some companies to withdraw from vaccine production, making this issue particularly important.

2. Novel Technology and Unknown Risks: COVID-19 vaccines employed relatively new approaches like mRNA technology, lacking long-term data compared to previous vaccines. The "development risk" concept—where defects cannot be discovered at the time products are distributed given existing scientific and technological standards—exists as a liability exemption reason, but the pandemic demanded even broader exemptions.

3. Introduction of "No-Fault" Compensation Systems: Many countries established "no-fault" compensation systems for health damage from vaccination in exchange for liability exemption. These aim for rapid victim compensation regardless of manufacturer fault. For example, the US PREP Act (Public Readiness and Emergency Preparedness Act) provided liability protection for COVID-19 countermeasure manufacturers, distributors, and administrators, accompanied by compensation programs.

The Relationship Between Immunity and Trust

Such manufacturing liability exemption had complex effects on public trust in product safety.

• Factors Contributing to Reduced Trust:
• Concerns About Lack of Accountability: When companies cannot be sued despite product problems, the natural question arises: "Why should we trust these products are safe?" Normally, manufacturer liability for product defects forms the foundation of consumer safety trust. When this principle doesn't apply, it raises concerns that companies lack incentive to maintain safety measures.
• Anxiety from Information Shortage: In addition to manufacturing liability exemption, non-disclosure clauses detailed below prevent product information disclosure, amplifying distrust.

• Arguments and Attempts to Maintain Trust:
• Public Health Urgency: Governments and public health authorities emphasized that pandemic emergency demanded rapid vaccine distribution. Individual risks were outweighed by community immunity benefits, and vaccinations were strongly recommended.
• "No-Fault" Compensation Systems: As described, compensation systems for unexpected injuries provide reassurance of relief availability, expected to maintain trust. However, these systems face challenges including "high hurdles for proving causation" and "limited compensation scope."

How Non-Disclosure Clauses Affect Trust

Vaccine procurement contracts between pharmaceutical companies and governments typically included broad non-disclosure agreements (NDAs).

• Contents and Reasons for Non-Disclosure Clauses:
• These clauses kept vaccine prices, supply schedules, intellectual property ownership, and detailed contract terms regarding legal responsibility confidential.
• Pharmaceutical companies argued non-disclosure was essential for protecting trade secrets, avoiding disadvantages in negotiations with other countries, and preventing supply impacts. Governments explained they had to accept non-disclosure clauses to secure vaccines.

• Transparency and Trust Impact:
• Transparency Deficit: Many contracts were heavily redacted or only leaked unofficially, making detailed public and parliamentary verification difficult. This severely undermined procurement process transparency.
• Amplified Suspicions: Non-disclosure clauses, combined with vaccine-related liability exemption, deepened suspicions about government-enterprise relationships. Citizens have the right to know how tax money is spent and under what conditions contracts are concluded, yet information secrecy created distrust: "Something is being hidden." Information secrecy creates potential for corruption and power abuse.
• Reduced Public Trust: During pandemics, citizen trust in government policy and product safety is extremely important. However, manufacturer liability exemption and information concealment through non-disclosure clauses undermined this trust, potentially contributing to vaccine hesitancy.

Summary

Manufacturing liability exemptions for pharmaceutical companies during the pandemic were introduced as unavoidable measures for promoting rapid medical product development and supply during emergencies. However, this ambiguated responsibility that manufacturers should normally bear for product safety, and non-disclosure clauses in procurement contracts severely compromised transparency regarding product safety and government accountability.

As a result, the question arose: "Why can people trust products made by companies they cannot sue?" and public trust wavered. While governments attempted to maintain trust through no-fault compensation systems, information shortage remains a major source of distrust. Ensuring transparency is an extremely important element for building trust relationships between government and citizens and between enterprises and consumers during public health crises.

During the pandemic (primarily COVID-19), pharmaceutical company liability exemption is a policy choice during emergencies and is not directly related to safety evidence.

In many countries, vaccine manufacturers received civil liability immunity (immunity) or government compensation (indemnification). This was a measure to promote rapid development and supply during emergencies where normal liability insurance functioned poorly. For example, the US PREP Act (Public Readiness and Emergency Preparedness Act) granted manufacturers broad immunity except for intentional misconduct (willful misconduct), transferring victim relief to government compensation programs (CICP, etc.). Similar contract and legal arrangements were made in EU countries, UK, and other nations, with AstraZeneca, Pfizer, and others concluding supply contracts including immunity and compensation clauses. [[1]](https://www.congress.gov/crs_external_products/IF/PDF/IF11905/IF11905.2.pdf)[[2]](https://www.reuters.com/article/world/astrazeneca-to-be-exempt-from-coronavirus-vaccine-liability-claims-in-most-count-idUSKCN24V2EL/)[[3]](https://ghiaa.org/mapguide-home/liability-and-indemnity-obligations-in-early-covid-19-vaccine-agreements/)

Why Can People Trust Products Made by "Non-Sueable" Companies?

Safety judgments rest on scientific evidence, regulatory authority review, and post-market surveillance, not legal immunity status. Immunity does not mean "companies bear no responsibility whatsoever for harm"; rather, governments and society assume the risk distribution during emergencies, with willful misconduct and gross negligence typically excluded. Companies retain safety and quality maintenance incentives through:

• Strict clinical trial review and approval by regulatory authorities (FDA, EMA, etc.).
• Continuous adverse effect monitoring systems (VAERS, etc.) collecting post-vaccination data.
• Companies' own reputation concerns and future business continuation (scandals directly impact stock price and contracts).
• Historical vaccine development records (normal vaccines also include partial immunity or compensation systems).

People trusted (or had trusted) primarily because of these independent scientific and institutional frameworks. Immunity itself doesn't guarantee safety; rather, it reflects the policy choice to "prioritize supply while handling damage through separate compensation." [[4]](https://www.chop.edu/vaccine-education-center/science-history/vaccine-science/common-questions-about-vaccine-liability)

Contract Non-Disclosure Clauses (NDA) and Trust Relationship

Supply contracts between pharmaceutical companies and governments include secrecy clauses (NDA) limiting transparency regarding prices, terms, and some data, with reported cases of transparency restrictions. This created information asymmetries and power imbalances, fueling public suspicion (e.g., AstraZeneca and Pfizer contracts with non-disclosed prices and terms). [[5]](https://nyujilp.org/non-disclosure-agreements-and-equitable-access-to-covid-19-vaccines/)

NDA purposes mainly protect commercial secrets (intellectual property, pricing strategies), but during crises, the point that "information about publicly-funded products is hidden" drew criticism as trust-damaging. Immunity plus NDA combinations strengthen corporate risk reduction and information control, increasing government and regulatory dependence. Maintaining trust requires independent third-party data disclosure, audits, and compensation process transparency.

Overall Relationship

• Immunity: Emergency response risk-shifting. Companies don't "neglect safety because they can't be sued"; scientific review and market/reputation mechanisms function assuming this basis.
• NDA: Commercial protection, but excessive application weakens accountability, easily inviting conspiracy theories and distrust.
• Trust Foundation: Ultimately, individuals rely on scientific data, authority independence, and personal risk assessment. While immunity enabled supply, transparency shortage weakened trust.

This relationship symbolizes emergency tradeoffs (rapid supply vs. complete accountability). Long-term trust maintenance requires balancing fair compensation system operation with information disclosure.